J&J Medical Connect
icotrokinra
J&J Medical Connect

Connect with us

Connect with us

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

icotrokinra

Medical Information

Icotrokinra - Treatment of Scalp Psoriasis

Last Updated: 02/16/2026

SUMMARY

  • Icotrokinra (JNJ-77242113) is a targeted oral peptide that selectively binds the interleukin-23 (IL-23) receptor and inhibits IL-23 pathway signaling.1 
  • The safety and efficacy of icotrokinra in patients with moderate to severe plaque psoriasis (PsO) was evaluated in the ICONIC-TOTAL (NCT06095102), ICONIC-LEAD (NCT06095115), ICONIC-ADVANCE 1 (NCT06143878), and ICONIC-ADVANCE 2 (NCT06220604) phase 3 clinical trials. Summarized below are data specific to scalp PsO across these studies.
    • In ICONIC-TOTAL, 66% vs 11% of patients in the icotrokinra vs placebo (PBO) groups, respectively, achieved a scalp-specific Investigator’s Global Assessment (ss-IGA) score of 0 or 1 (ss-IGA 0/1, clear or almost clear skin) at week 16 (treatment difference, 56%; 95% confidence interval [CI], 44.8-64.4; P<0.001).1 
    • In ICONIC-LEAD, 72% vs 15% of patients in the icotrokinra vs PBO groups, respectively, achieved ss-IGA 0/1 response at week 16 (treatment difference, 57%; 95% CI, 49.9–63.1; P<0.001).2 
    • In ICONIC-ADVANCE 1, 72% vs 21% of patients in the icotrokinra vs PBO groups, respectively, achieved ss-IGA 0/1 response at week 16 (treatment difference, 51%; 95% CI, 42-59; P<0.001).3,4 
    • In ICONIC-ADVANCE 2, 74% vs 18% of patients in the icotrokinra vs PBO groups, respectively, achieved ss-IGA 0/1 response at week 16 (treatment difference, 56%; 95% CI, 44-65; P<0.001).3,4 

CLINICAL DATA

ICONIC-TOTAL

Gooderham et al (2025)1 and Lain et al (2025)5 evaluated the efficacy and safety of oral icotrokinra 200 mg once daily in patients ≥12 years of age with plaque PsO affecting special sites (scalp, genitals, and/or palms of the hands and soles of the feet) in an ongoing phase 3, multicenter, randomized, double-blind, PBO-controlled study.

Study Design/Methods

  • Key inclusion criteria:1 
    • Age ≥12 years with plaque PsO diagnosed for ≥26 weeks at screening; candidate for phototherapy or systemic therapy with an inadequate response to ≥1 topical therapy
    • Total body surface area (BSA) involvement ≥1% and Investigator’s Global Assessment (IGA) score ≥2
    • Involvement of ≥1 high-impact sites with at least moderate severity (ss-IGA score ≥3, static Physician’s Global Assessment of Genitalia [sPGA-G] score ≥3, Physician’s Global Assessment of hands and feet [hf-PGA] ≥3)
  • Patients were randomized (2:1) to receive oral icotrokinra 200 mg or PBO once daily, with PBO crossover to icotrokinra at week 16.1 
  • The primary and select secondary outcome measures are described in Table: Select ICONIC-TOTAL Outcome Measures at Week 16.1

Select ICONIC-TOTAL Outcome Measures at Week 161  
Primary Endpoint
Percentage of patients who achieved an IGA score of clear (0) or minimal (1) and ≥2-grade improvement from baseline
Select Secondary Endpoints
Percentage of patients who achieved ss-IGA score of absence of disease (0) or very mild disease (1)
Percentage of patients who achieved PSSI 90 response
Percentage of patients who achieved ≥4-point improvement from baseline in Scalp Itch NRS score
Abbreviations: IGA, Investigator’s Global Assessment; NRS, numeric rating scale; PSSI, Psoriasis Scalp Severity Index; ss-IGA, scalp-specific Investigator’s Global Assessment.

Results

Patient Characteristics
  • A total of 311 patients (icotrokinra, n=208; PBO, n=103) were included in the study, with 64% being male and 78% being White. The mean age was 45 years (6 patients were ≥12 and <18 years old).1 
  • In the icotrokinra and PBO groups, respectively, 80% (167/208) and 83% (85/103) of patients had at least moderate scalp PsO at baseline (ss-IGA score ≥3).1 
Efficacy
  • Primary endpoint: 57% (118/208) vs 6% (6/103) of patients receiving icotrokinra vs PBO, respectively, achieved IGA 0/1 response at week 16 (treatment difference, 51% [95% CI, 42.1-58.8]; P< 0.001).1 
  • Select secondary endpoints are described in Table: Select ICONIC-TOTAL Endpoints.1,5  

Select ICONIC-TOTAL Endpoints1,5  
ICO
N=167
PBO
N=85
Treatment Difference (95% CI)
or P-value
PBO→ICO Crossovera
N=75
Proportion of patients achieving endpoint, %
  ss-IGA 0/1b
Week 16
66
11
56% (44.8-64.4)
P<0.001c
-
    Week 52
72
-
-
71
  ss-IGA 0b
Week 16
49
2
Nominal P<0.001c,d
-
    Week 52
57
-
-
61
  PSSI 90b
Week 16
58
6
52% (41.7-60.3)
P=0.008c
-
  CMI in Scalp Itch NRSe
Week 16
59
9
50% (37.8-60.6) P=0.008c
-
Abbreviations: BSA, body surface area; CI, confidence interval; CMI, clinically meaningful improvement (≥4-point improvement from baseline); ICO, icotrokinra; IGA, Investigator’s Global Assessment; NRS, numeric rating scale; PBO, placebo; PSSI, Psoriasis Scalp Severity Index; PSSI 90, reduction from baseline of ≥90% in the PSSI score; ss-IGA, scalp-specific Investigator’s Global Assessment.aPatients crossed over from PBO to ICO at week 16.bAmong patients with a baseline ss-IGA score ≥3cP-values were calculated based on Cochran-Mantel-Haenszel chi-square test stratified by high-impact site involvement (if applicable), geographic region, and/or BSA category (if applicable).dThis endpoint was not adjusted for multiple comparisons. Therefore, the P-value displayed is nominal, and statistical significance has not been established.eAmong patients with a baseline Scalp Itch NRS score ≥4 and a ss-IGA score ≥3 (ICO, N=131; PBO, N=58).
Safety
  • Through week 16, 50% (105/208) of patients receiving icotrokinra and 45% (46/103) of patients receiving PBO reported ≥1 adverse events (AE).5 
  • Through week 52, 74% (153/208) of patients receiving icotrokinra and 68% (204/300) of patients in the icotrokinra combined group reported ≥1 AE (see Table: Adverse Events in ICONIC-TOTAL through Week 52).5 
  • No new safety signals were identified through week 52.5 

Adverse Events in ICONIC-TOTAL through Week 525
PBO-Controlled
Crossover
Active Comparator
ICO
N=208
PBO
N=103
PBO→ICO N=92
ICO
N=208
ICO Combineda N=300
Treatment period
W0-16
W16-52
W0-52
Mean weeks of follow-up
16
16
36
49
45
Any AE, n (%)
105 (50)
46 (45)
51 (55)
153 (74)
204 (68)
SAEs, n (%)
1 (<1)
2 (2)
1 (1)
6 (3)
7 (2)
AEs leading to discontinuation, n (%)
6 (3)
4 (4)
0
7 (3)
7 (2)
Infections, n (%)
59 (28)
23 (22)
39 (42)
106 (51)
145 (48)
Serious infections, n (%)
0
1 (1)
0
0
0
Gastrointestinal AEs, n (%)
15 (7)
8 (8)
7 (8)
21 (10)
28 (9)
Malignancy, n (%)b
1 (<1)
0
0
2 (1)
2 (1)
Abbreviations: AE, adverse event; ICO, icotrokinra; PBO, placebo; SAE, serious adverse event; W, week.
aIncludes data for ICO-randomized patients through week 52 and for PBO-to-ICO patients from week 16 through week 52.
bMalignancy includes chronic lymphocytic leukemia and malignant melanoma in situ.

ICONIC-LEAD

Bissonnette et al (2025)2 and Soung et al (2025)6,7 evaluated the efficacy and safety of oral icotrokinra 200 mg daily in patients ≥12 years of age with moderate to severe plaque PsO in an ongoing phase 3, multicenter, randomized, double-blind, placebo PBO-controlled study with randomized withdrawal and retreatment.

Study Design/Methods

  • Key inclusion criteria:2 
    • Age ≥12 years with moderate to severe plaque PsO diagnosed for ≥26 weeks at screening; candidate for phototherapy or systemic therapy
    • Total BSA involvement ≥10%
    • Total PASI score ≥12
    • IGA score ≥3
  • Patients were randomized (2:1) to receive oral icotrokinra 200 mg or PBO once daily, with PBO crossover to icotrokinra at week 16.2 
  • Coprimary endpoints: IGA 0/1 with a ≥2-grade improvement from baseline to week 16 and PASI 90 at week 16.2 
  • Select key secondary endpoint: ss-IGA 0/1 with a ≥2-grade improvement from baseline, assessed among those with baseline ss-IGA score ≥2.2 

Results

Patient Characteristics
  • A total of 684 (icotrokinra, n=456; PBO, n=228) patients were included in the study, with 65% being male, 72% being White, and a mean age of 43 years.2 
  • In the icotrokinra group, 59% (268/451) and 17% (76/451) of patients had moderate or severe scalp PsO, respectively; while 51% (116/227) and 22% (49/227) of patients in the PBO group had moderate or severe scalp PsO, respectively.2 
Efficacy – Overall Population

Select ICONIC-LEAD Endpoints2 
ICO
N=456
PBO
N=228
Treatment Difference
(95% CI)
Proportion of patients achieving endpoint, n (%)
  IGA 0/1 with a ≥2-grade improvement from baseline
    Week 16 – coprimary endpoint
295 (65)
19 (8)
56% (50.4-61.7)
P<0.001a
  PASI 90
    Week 16 – coprimary endpoint
226 (50)
10 (4)
45% (39.5-50.4)
P<0.001a
ss-IGA 0/1 and ≥2-grade improvement from baselineb
    Week 16
293/405 (72)
30/200 (15)
57% (49.9–63.1)
P<0.001a
Abbreviations: CI, confidence interval; ICO, icotrokinra; IGA, Investigator’s Global Assessment; PASI, Psoriasis Area Severity Index; PBO, placebo; QD, daily; ss-IGA, scalp-specific Investigator’s Global Assessment.
aP-values were calculated based on Cochran-Mantel-Haenszel chi-square test stratified by age group, baseline weight category (adults only), and geographic region (if applicable). P-values for key secondary endpoints were adjusted for multiplicity.
bAmong patients with baseline ss-IGA score ≥2.
Efficacy – High-Impact Site Involvement Subgroup Analysis

ICONIC-LEAD Subgroup Analysis - Select High-impact Site Response Rates6
ICO
N=344
PBO
N=165
Treatment Difference
(95% CI)
Proportion of patients achieving endpoint, %
  ss-IGA 0/1a
    Week 16
72
14
58% (50.8-64.8)b
Nominal P<0.001c
    Week 24
81
-
-
  ss-IGA 0a
    Week 16
53
9
44% (36.5-50.1)b
Nominal P<0.001c
    Week 24
65
-
-
Abbreviations: CI, confidence interval; CMH, Cochran-Mantel-Haenszel; ICO, icotrokinra; PBO, placebo; ss-IGA, scalp-specific Investigator’s Global Assessment.
aAmong patients with a baseline ss-IGA score ≥3.
bTreatment difference and 95% CI (using Miettinen-Nurminen method) were calculated adjusting for age group, baseline weight category for adults, and geographic region using Mantel-Haenszel weights.cP-values were based on CMH test stratified by age group, baseline weight category for adults, and geographic region. The endpoint was not controlled for multiple comparisons. Therefore, the P-value is nominal, and statistical significance has not been established.
Safety – Overall Population
  • Through week 16, 50% and 49% of patients in the icotrokinra and PBO groups, respectively reported ≥1 AE, with nasopharyngitis and upper respiratory tract infection being the most common.7 
    • Through week 16, 23% (107/456) and 22% (51/228) of patients in the icotrokinra and PBO groups, respectively, reported an infection.2 
  • The icotrokinra AE profile through week 52 was consistent with that observed through week 16 (see Table: Adverse Events in the Overall ICONIC-LEAD Population through Week 52).2,7,8 

Adverse Events in the Overall ICONIC-LEAD Population through Week 522,7,8 
PBO-Controlled
(Adults & Adolescents)
Active Treatment
(Adults & Adolescents)
ICO Responders Re-Randomized at W24 (Adults)
ICO
N=456
PBO
N=228
ICOa
N=213
ICO
N=456
ICO→ICO N=168
ICO→PBOb N=172
Treatment period
W0-16
W16-52
W0-52
W24-52
Mean weeks of follow-up
16
16
35
43
28
28
Any AE
226 (50)
112 (49)
132 (62)
313 (69)
92 (55)
82 (48)
  Most common AEs (≥5%)
    Nasopharyngitis
31 (7)
15 (7)
23 (11)
64 (14)
21 (12)
20 (12)
    URTI
30 (7)
16 (7)
24 (11)
52 (11)
9 (5)
15 (9)
SAEc
6 (1)
6 (3)
4 (2)
16 (4)
3 (2)
5 (3)
Serious infection
1 (<1)
0
1 (<1)
1 (<1)
0
1 (1)
AE leading to discontinuationd
6 (1)
1 (<1)
4 (2)
10 (2)
1 (1)
3 (2)
Gastrointestinal AEe
26 (6)
13 (6)
9 (4)
51 (11)
7 (4)
8 (5)
Active tuberculosis
0
0
0
0
0
0
Malignancyf
2 (<1)
0
0
2 (<1)
0
0
Abbreviations: AE, adverse events; ICO, icotrokinra; PBO, placebo; SAEs, serious adverse events; URTI, upper respiratory tract infection; W, week.Note: Data are n (%), unless otherwise specified
aIncludes data after week 16 for PBO-randomized patients who crossed over to receive ICO.bCombined withdrawal and retreatment group.cSAEs through week 16 included acute cholecystitis, concussion, craniofacial fracture, pelvic fracture, psoriasis, and hypertensive urgency in the PBO group; and adenocarcinoma of the colon, prostate cancer, pancreatitis, bacterial gastroenteritis, arthralgia, and subarachnoid hemorrhage in the ICO group.
dAEs leading to discontinuation through week 16 included blood glucose increase in the PBO group; and adenocarcinoma of the colon, prostate cancer, hypertriglyceridemia, subarachnoid hemorrhage, erectile dysfunction, and psoriasis in the ICO group.eBased on gastrointestinal disorders system organ class.
fIncluded adenocarcinoma of the colon (1 patient who had a history of smoking; the patient reported mild gastroenteritis during screening, severe colitis starting on study day 7, and severe ileus on day 14 leading up to the diagnosis of grade 3 adenocarcinoma of the colon on day 19) and prostate cancer (1 patient who had a history of smoking and a family history of prostate cancer; grade 1 prostate cancer was diagnosed on study day 48).

ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2

Stein Gold et al (2025)3 reported results through week 24 from ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2, two phase 3, multicenter, randomized, double-blind clinical trials evaluating the efficacy and safety of oral icotrokinra 200 mg once daily compared to PBO and deucravacitinib for the treatment of adults with moderate to severe plaque PsO.

Study Design/Methods

  • Both studies employed identical enrollment criteria.3 
    • Key inclusion criteria: age ≥18 years with moderate to severe plaque PsO diagnosed for ≥26 weeks at screening who were candidates for phototherapy or systemic therapy; total BSA involvement ≥10%, total PASI score ≥12, and IGA score ≥3.
  • Patients were randomized to oral icotrokinra 200 mg once daily, PBO, or oral deucravacitinib 6 mg, with PBO crossover to icotrokinra at week 16 and deucravacitinib crossover to icotrokinra at week 24. ADVANCE 1 and ADVANCE 2 utilized different randomization ratios (2:1:2 and 4:1:4, respectively).3 
  • Coprimary endpoints: IGA 0/1 with a ≥2-grade improvement from baseline to week 16 and PASI 90 at week 16 (icotrokinra group versus PBO group).3 
  • Select key secondary endpoint: ss-IGA 0/1 with a ≥2-grade improvement from baseline, assessed among those with baseline ss-IGA score ≥2 (icotrokinra group versus PBO group).3 

Results

Patient Characteristics
  • A total of 774 and 731 patients were randomized to ADVANCE 1 (icotrokinra n=311; PBO n=156; deucravacitinib n=307) and ADVANCE 2 (icotrokinra n=322; PBO n=82; deucravacitinib n=327), respectively.3 
  • Across ADVANCE 1 and ADVANCE 2, most patients were male (68% and 68%, respectively) and White (74% and 83%, respectively). The mean age at baseline was 46.7 and 46.1 years in ADVANCE 1 and ADVANCE 2, respectively.3 
  • In the icotrokinra groups, 57% and 52% of patients had moderate scalp PsO in ADVANCE 1 and ADVANCE 2, respectively, while 13% and 12% had severe scalp PsO. In the PBO groups, 54% and 59% of patients had moderate scalp PsO in ADVANCE 1 and ADVANCE 2, respectively, while 12% and 7% had severe scalp PsO.3 
Efficacy

Select ICONIC-ADVANCE 1 Endpoints at Week 16 (Icotrokinra vs PBO)3,4 
n (%)
ICO
N=311
PBO
N=156
Treatment Difference
(95% CI)
Adjusted
P-value
Primary Endpoints
IGA 0/1
213 (68)
17 (11)
58 (50-64)
P<0.0001
PASI 90
171 (55)
6 (4)
51 (44-57)
P<0.0001
Key Secondary Endpoints
ss-IGA 0/1a
189 (72)
28 (21)
51 (42-59)
P<0.001
Abbreviations: CI, confidence interval; ICO, icotrokinra; IGA, Investigator’s Global Assessment; PASI, Psoriasis Area Severity Index; PBO, placebo; ss-IGA, scalp-specific Investigator’s Global Assessment.
aAmong the 261 and 134 patients with a baseline ss-IGA score ≥2 in the ICO and PBO groups, respectively.

Select ICONIC-ADVANCE 2 Endpoints at Week 16 (Icotrokinra vs PBO)3,4 
n (%)
ICO
N=322
PBO
N=82
Treatment Difference
(95% CI)
Adjusted
P-value
Primary Endpoints
IGA 0/1
227 (70)
7 (9)
62% (53, 69)
P<0.0001
PASI 90
184 (57)
1 (1)
56% (48, 62)
P<0.0001
Key Secondary Endpoints
ss-IGA 0/1a
199 (74)
13 (18)
56% (44, 65)
P<0.001
Abbreviations: CI, confidence interval; ICO, icotrokinra; IGA, Investigator’s Global Assessment; PASI, Psoriasis Area Severity Index; PBO, placebo; ss-IGA, scalp-specific Investigator’s Global Assessment.
aAmong the 270 and 71 patients with a baseline ss-IGA score ≥2 in the ICO and PBO groups, respectively.
Safety
  • A total of 632, 237, and 634 patients in the icotrokinra, PBO, and deucravacitinib groups were included in the combined safety analysis set.3 
  • Through week 16, 48% (303/632), 57% (136/237), and 57% (360/634) of patients receiving icotrokinra, PBO, and deucravacitinib, respectively, reported ≥1 AE(s).3 
    • The most common AEs were nasopharyngitis, upper respiratory tract infection, and headache.
    • Gastrointestinal AEs occurred in 7% (45/632), 6% (15/237), and 10% (63/634) of patients in the icotrokinra, PBO, and deucravacitinib groups, respectively.
  • Through week 24, AE rates were lower in the icotrokinra group versus the deucravacitinib group (57% vs 65%), and no safety signals were identified.3 
  • See Table: Combined AEs from the ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 Safety Analysis Sets.

Combined AEs from the ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 Safety Analysis Sets3 
PBO-Controlled
Active Comparator-Controlled
Crossover
ICO
PBO
Deucra
ICO
Deucra
PBO→ICO
Number of patientsa
632
237
634
632
634
215
Treatment period
W0-16
W0-24
W16-24
Mean weeks of follow up (SD)
16 (1.88)
16 (2.69)
16 (2.25)
24 (3.26)
23 (3.94)
8 (0.58)
≥1 AE, n (%)
303 (48)
136 (57)
360 (57)
359 (57)
411 (65)
60 (28)
AEs occurring in ≥5% of patients in any treatment group, n (%)
    Headache
26 (4)
11 (5)
19 (3)
28 (4)
20 (3)
3 (1)
    Nasopharyngitis
37 (6)
13 (5)
58 (9)
56 (9)
77 (12)
8 (4)
    URTI
23 (4)
8 (3)
33 (5)
32 (5)
49 (8)
7 (3)
Serious AE, n (%)
14 (2)
4 (2)
14 (2)
18 (3)
20 (3)
3 (1)
    Serious infectionb
1 (<1)
1 (<1)
4 (1)
3 (<1)
4 (1)
0
AE resulting in discontinuation, n (%)
13 (2)
12 (5)
14 (2)
15 (2)
17 (3)
0
GI AEs, n (%)
45 (7)
15 (6)
63 (10)
55 (9)
80 (13)
5 (2)
Malignancy, n (%)c
3 (<1)
1 (<1)
1 (<1)
3 (<1)
2 (<1)
0
Active TB, n (%)
0
0
0
0
0
0
Abbreviations: AE, adverse events; Deucra, deucravacitinib; GI, gastrointestinal; ICO, icotrokinra; PBO, placebo; SD, standard deviation; TB, tuberculosis; URTI, upper respiratory tract infection; W, week.
aThe safety analysis set included all randomized and treated participants.bSerious infections included bacterial arthritis (PBO group), campylobacter colitis (Deucra group), viral infection (Deucra group), infection exacerbated by chronic obstructive airways disease (ICO group), lower respiratory tract infection (Deucra group), viral upper respiratory tract infection (Deucra group), and pneumonia (ICO group).cDetails on malignancies reported through Week 24 of both studies are provided as early as Week 4.4 
  • Through week 24, there were 6 instances of malignancy reported across ICONIC-ADVANCE 1 and ICONIC-ADVANCE 24:
    • Three in the icotrokinra group (pancreatic carcinoma, breast cancer, and keratoacanthoma)
    • One in the PBO group (invasive ductal breast carcinoma)
    • Two in the deucravacitinib group (right buccal squamous cell carcinoma and malignant melanoma in situ)
    • All events were considered unrelated to study treatments by investigators.

LITERATURE SEARCH

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) was conducted on 29 January 2026.

 

References

Show
1 Gooderham M, Lain E, Bissonnette R, et al. Targeted oral peptide icotrokinra for psoriasis involving high-impact sites. NEJM Evid. 2025;4(12).  
2 Bissonnette R, Soung J, Hebert AA, et al. Oral icotrokinra for plaque psoriasis in adults and adolescents. N Engl J Med. 2025;393(18):1784-1795.  
3 Stein Gold L, Armstrong AW, Bissonnette R, et al. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. Lancet. 2025;406(10510):1363-1374.  
4 Stein Gold L, Armstrong AW, Bissonnette R, et al. Supplement to: Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. Lancet. 2025;406(10510):1363-1374.  
5 Lain E, Warren RB, Gooderham M, et al. Durability of response to the targeted oral peptide icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings. Poster presented at: Fall Clinical Dermatology Conference; October 23-26, 2025; Las Vegas, NV.  
6 Soung J, Chih-ho Hong H, Ehst B, et al. Treatment of plaque psoriasis involving high-impact sites with icotrokinra: subgroup analyses of the phase 3, ICONIC-LEAD trial. Poster presented at: AAD Innovation Academy; July 10-13, 2025; Chicago, IL.  
7 Soung J, Cui Y, Bissonnette R, et al. Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: randomized treatment withdrawal in adults (weeks 24-52) and continuous treatment in adolescents (through week 52) from the phase 3, ICONIC-LEAD trial. Oral Presentation presented at: European Academy of Dermatology and Venereology (EADV); September 17-20, 2025; Paris, France.  
8 Bissonnette R, Soung J, Adelaide H, et al. Icotrokinra, a targeted oral peptide that selectively blocks the interleukin-23-receptor, for the treatment of moderate-to-severe plaque psoriasis: results through week 24 of the phase 3, randomized, double-blind, placebo-controlled ICONIC-LEAD trial. Oral Presentation presented at: American Academy of Dermatology; March 7-11, 2025; Orlando, FL.